Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients.

scientific article published in November 1998

Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/515006
P698PubMed publication ID9827284
P5875ResearchGate publication ID13460016

P50authorJohn RexQ67918633
P2093author name stringM Lozano-Chiu
M D Martins
P2860cites workAntiretroviral effect of zidovudine-didanosine combination on blood and lymph nodesQ40913624
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectcandidiasisQ273510
Candida albicansQ310443
P304page(s)1291-1294
P577publication date1998-11-01
P1433published inClinical Infectious DiseasesQ5133764
P1476titleDeclining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients
P478volume27

Reverse relations

cites work (P2860)
Q34335250A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America
Q46758165A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
Q34594076Antifungal drug resistance of pathogenic fungi.
Q34807486Antifungal drug resistance to azoles and polyenes
Q34335225Antifungal resistance among Candida species
Q34492756CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1.
Q48163274Candida glabrata Biofilms: How Far Have We Come?
Q40539777Candida species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico
Q34505582Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Q34936576Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Q34993877Clinical relevance of mechanisms of antifungal drug resistance in yeasts
Q35633925Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans
Q34423476Defective IL-17- and IL-22-dependent mucosal host response to Candida albicans determines susceptibility to oral candidiasis in mice expressing the HIV-1 transgene
Q51716718Diagnosis and Management of Candida and Other Fungal Infections of the Head and Neck.
Q42224074Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis
Q34490092Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Q27318203Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence
Q36238025Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis.
Q33859215Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
Q35920633Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.
Q37333439Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene
Q36900988Mouse model of oropharyngeal candidiasis
Q35782813Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment
Q38363105Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies
Q34041589Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico
Q34521587Oral lesions of HIV disease and HAART in industrialized countries
Q34303424Oropharyngeal Candida colonization in human immunodeficiency virus infected patients
Q33746435Oropharyngeal candidiasis in the era of antiretroviral therapy
Q34992078Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility
Q46656032Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons.
Q33894467Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America
Q34569070Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Q36821383The use of caspofungin in HIV-infected individuals
Q37180338Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)
Q42002376Transcriptional landscape of trans-kingdom communication between Candida albicans and Streptococcus gordonii.
Q44322984Treatment of opportunistic infections among adult and adolescent patients infected with the human immunodeficiency virus in the era of highly active anti-retroviral therapy
Q34085884Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.
Q43785347Two-year surveillance on fluconazole susceptibility of Candida spp isolates in a general and university hospital in Rome
Q37060341Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Search more.